Recent Updates — BYSI
BeyondSpring Inc. announced that the FDA granted Fast Track designation for Plinabulin combined with docetaxel in post-immunotherapy non-squamous NSCLC patients without actionable genomic alterations. Concurrently, the company entered into a Share Purchase and Collaboration Agreement to sell its wholly owned subsidiary BeyondSpring Ltd., which holds interests in Chinese subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd., to Biolin Investment Limited for no cash consideration. In exchange, Biolin will fund the China portion of the global Phase 3 DUBLIN-4 trial, expected to enroll approximately 221 patients, representing roughly half of the total planned enrollment of 442 patients. The transaction aims to substantially reduce BeyondSpring's cash requirements while securing access to clinical data for its registration strategy. Additionally, BeyondSpring established an at-the-market equity offering program allowing it to sell up to 9,200,000 ordinary shares through Citizens JMP Securities LLC with a commission of up to 3.0%. BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing innovative cancer therapies.
BeyondSpring Inc. received a written notification from Nasdaq on September 17, 2026, indicating non-compliance with the minimum bid price requirement because its ordinary shares closed below $1.00 for 30 consecutive business days. The company has an 180-day compliance period until March 16, 2027, to restore the share price to at least $1.00 for ten consecutive trading days. Failure to regain compliance may result in delisting or a request for an additional extension. This event does not immediately affect business operations, but the company is evaluating options to meet listing standards. BeyondSpring Inc. operates in the biotechnology industry, focusing on the development of cancer treatments.
BeyondSpring Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $1.8 million compared to $1.9 million in the prior year period. Research and development expenses remained flat at $1.0 million, while general and administrative expenses decreased by $0.1 million to $0.8 million due to lower legal and consulting costs. Cash, cash equivalents, and short-term investments declined to $6.5 million from $12.6 million as of December 31, 2025. The company highlighted clinical data for Plinabulin presented at ASCO 2026 and AACR 2026, supporting its confirmatory Phase 3 DUBLIN-4 study in non-squamous NSCLC. Additionally, BeyondSpring announced a leadership transition effective July 1, 2026, appointing Min Qiu as CEO, Dr. Jiangwen (Jen) Majeti as Vice Chairman, and Na Li as CFO to focus on advancing the DUBLIN-4 program. BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer.
BeyondSpring Inc. finalized the compensatory arrangements for newly appointed Chief Executive Officer Min Qiu, providing an annual salary of $100,000 and a target annual bonus of 30% of base salary. The agreement includes a grant of 100,000 ordinary shares via options that vest in four equal annual installments. BeyondSpring Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions.